{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:09:40Z","timestamp":1760918980653,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.nucmedbio.2022.108309","type":"journal-article","created":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T14:02:34Z","timestamp":1669471354000},"page":"108309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of [18F]FMTEB in Sprague Dawley rats as a PET tracer for metabotropic glutamate receptor 5"],"prefix":"10.1016","volume":"116-117","author":[{"given":"Anna","family":"Krzyczmonik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina E.","family":"Grafinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarita","family":"Forsback","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merja","family":"Haaparanta-Solin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Gouverneur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"L\u00f3pez-Pic\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olof","family":"Solin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2022.108309_bb0005","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00702-014-1180-8","article-title":"Glutamate as a neurotransmitter in the healthy brain","volume":"121","author":"Zhou","year":"2014","journal-title":"J Neural Transm"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.109.002451","article-title":"Glutamate receptor ion channels: structure, regulation, and function","volume":"62","author":"Traynelis","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0301-0082(00)00067-8","article-title":"Glutamate uptake","volume":"65","author":"Danbolt","year":"2001","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature13396","article-title":"Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain","volume":"511","author":"Dor\u00e9","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0163-7258(03)00038-X","article-title":"Evolution, structure, and activation mechanism of family 3\/C G-protein-coupled receptors","volume":"98","author":"Pin","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev.pharmtox.37.1.205","article-title":"Pharmacology and functions of metabotropic glutamate receptors","volume":"37","author":"Conn","year":"1997","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0040","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s11307-005-0005-4","article-title":"Screening cascade and development of potential positron emission tomography radiotracers for mGluR5: in vitro and in vivo characterization","volume":"7","author":"Patel","year":"2005","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0045","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1523\/JNEUROSCI.22-12-05219.2002","article-title":"The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentiation in the lateral amygdala","volume":"22","author":"Rodrigues","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0304-3940(93)90227-C","article-title":"Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain","volume":"163","author":"Shigemoto","year":"1993","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0055","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/cne.903540207","article-title":"Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons","volume":"354","author":"Testa","year":"1995","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0060","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1523\/JNEUROSCI.22-13-05669.2002","article-title":"Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism","volume":"22","author":"Breysse","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0065","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0006-3223(01)01362-2","article-title":"Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders","volume":"51","author":"Moghaddam","year":"2002","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.nucmedbio.2022.108309_bb0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/jon.12563","article-title":"18F-FPEB PET\/CT shows mGluR5 upregulation in Parkinson's disease","volume":"29","author":"Kang","year":"2019","journal-title":"J Neuroimaging"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF03033782","article-title":"The role of group I metabotropic glutamate receptors in neuronal excitotoxicity in Alzheimer's disease","volume":"7","author":"Tsai","year":"2005","journal-title":"Neurotox Res"},{"issue":"2","key":"10.1016\/j.nucmedbio.2022.108309_bb0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0301-0082(03)00087-X","article-title":"The neurobiology and control of anxious states","volume":"70","author":"Millan","year":"2003","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0085","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0091-3057(02)00828-6","article-title":"Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone","volume":"73","author":"Brodkin","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0090","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.bjp.0703923","article-title":"Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist","volume":"132","author":"Tatarczy\u0144ska","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0095","first-page":"449","article-title":"Metabotropic glutamate receptor 5 and glutamate involvement in major depressive disorder: a multimodal imaging study","volume":"2","author":"Abdallah","year":"2017","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fnins.2015.00086","article-title":"The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: combining preclinical evidence with human positron emission tomography (PET) studies","volume":"9","author":"Terbeck","year":"2015","journal-title":"Front Neurosci"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13041-017-0293-z","article-title":"Targeting metabotropic glutamate receptors for novel treatments of schizophrenia","volume":"10","author":"Maksymetz","year":"2017","journal-title":"Mol Brain"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tips.2008.10.006","article-title":"Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00726-006-0319-9","article-title":"The role of group I metabotropic glutamate receptors in schizophrenia","volume":"32","author":"Pietraszek","year":"2007","journal-title":"Amino Acids"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40673-018-0082-1","article-title":"Metabotropic glutamate receptor 5 tracer [18F]-FPEB displays increased binding potential in postcentral gyrus and cerebellum of male individuals with autism: a pilot PET study","volume":"5","author":"Fatemi","year":"2018","journal-title":"Cerebellum Ataxias"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/syn.20147","article-title":"Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers","volume":"56","author":"Hamill","year":"2005","journal-title":"Synapse"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0130","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1021\/jm00009a001","article-title":"Metabotropic glutamate receptors: novel targets for drug development","volume":"38","author":"Knopfel","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0135","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.3390\/molecules25204749","article-title":"A review of molecular imaging of glutamate receptors","volume":"25","author":"Kim","year":"2020","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.nucmedbio.2022.108309_bb0140","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00259-015-3301-5","article-title":"Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging","volume":"43","author":"Pillai","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0145","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.nucmedbio.2005.05.004","article-title":"Methoxyphenylethynyl, methoxypyridylethynyl and phenylethynyl derivatives of pyridine: synthesis, radiolabeling and evaluation of new PET ligands for metabotropic glutamate subtype 5 receptors","volume":"32","author":"Yu","year":"2005","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0150","first-page":"S188","article-title":"Synthesis and evaluation of [11C]M-FPEP as a PET ligand for imaging the metabotropic glutamate receptor subtype 5 (MGLUR5)","volume":"46","author":"Ametamey","year":"2003","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0155","first-page":"698","article-title":"Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5","volume":"47","author":"Ametamey","year":"2006","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.nucmedbio.2022.108309_bb0160","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2967\/jnumed.112.107995","article-title":"18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry","volume":"54","author":"Wong","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0165","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.neuroimage.2012.02.085","article-title":"Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers","volume":"61","author":"K\u00e5gedal","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0170","doi-asserted-by":"crossref","first-page":"7751","DOI":"10.1002\/anie.201404436","article-title":"A general copper-mediated nucleophilic 18F-fluorination of arenes","volume":"53","author":"Tredwell","year":"2014","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0175","doi-asserted-by":"crossref","first-page":"8361","DOI":"10.1039\/C6CC03295H","article-title":"Enhanced copper-mediated 18F-fluorination of aryl boronic esters provides eight radiotracers for PET applications","volume":"52","author":"Preshlock","year":"2016","journal-title":"Chem Commun"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.apradiso.2015.01.025","article-title":"[18F]FPEB and [18F]FDEGPECO comparative study of mGlu5 quantification in rodent brain","volume":"98","author":"Kang","year":"2015","journal-title":"Appl Radiat Isotop"},{"year":"2019","series-title":"Guideline for elemental impurities Q3D(R1)","key":"10.1016\/j.nucmedbio.2022.108309_bb0185"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0190","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/syn.20445","article-title":"Synthesis and preliminary biological evaluation of 3-[18F]Fluoro-5-(2-pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5","volume":"61","author":"Wang","year":"2007","journal-title":"Synapse"},{"key":"10.1016\/j.nucmedbio.2022.108309_bb0195","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2967\/jnumed.115.162636","article-title":"Preclinical evaluation and quantification of 18F-FPEB as a radioligand for PET imaging of the metabotropic glutamate receptor 5","volume":"56","author":"de Laat","year":"2015","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805122021035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805122021035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:30:58Z","timestamp":1760848258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805122021035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":39,"alternative-id":["S0969805122021035"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.108309","relation":{},"ISSN":["0969-8051"],"issn-type":[{"type":"print","value":"0969-8051"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of [18F]FMTEB in Sprague Dawley rats as a PET tracer for metabotropic glutamate receptor 5","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.108309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108309"}}